human cytomegalovirus immunoglobulin (Kamada Ltd.)

Human cytomegalovirus immunoglobulin (CMVIG) is a plasma-derived, hyperimmune intravenous immunoglobulin (IVIG) preparation containing high titers of neutralizing antibodies (primarily IgG1 and IgG3) directed against human cytomegalovirus (HCMV). It is prepared from pooled human plasma of screened donors selected for high titers of anti-CMV antibodies. CMVIG provides passive immunity by binding to viral envelope glycoproteins (such as glycoprotein B and the gH/gL/UL128-131 pentameric complex), thereby neutralizing extracellular virus particles, preventing viral entry into host cells, and promoting phagocytosis and antibody-dependent cellular cytotoxicity (ADCC). It is primarily indicated for the prophylaxis of cytomegalovirus disease associated with solid organ transplantation (including kidney, lung, liver, pancreas, and heart) and has been used as an adjunctive or salvage therapy for CMV pneumonitis and other severe CMV infections in immunocompromised patients.

Brand names

CMV Immunoglobulin-VFCymvigoCytogamCytoglobinCytomegatectCytotectCytotect CPIvegam-cmvMegalotectMegalotect CP

Other names

CMV-IGIVCMVIGanti-HCMV human immunoglobulincytomegalovirus immune globulincytomegalovirus immune globulin intravenous (human)cytomegalovirus immunoglobulinhuman anti-cytomegalovirus immunoglobulinhuman cytomegalovirus immunoglobulin